Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer

[1]  Yanfeng Gao,et al.  Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis. , 2010, Immunology letters.

[2]  D. Schlessinger,et al.  PLAC1 (Placenta‐specific 1): a novel, X‐linked gene with roles in reproductive and cancer biology , 2010, Prenatal diagnosis.

[3]  Yanfeng Gao,et al.  Identification of a new broad-spectrum CD8+ T cell epitope from over-expressed antigen COX-2 in esophageal carcinoma. , 2009, Cancer letters.

[4]  B. Ni,et al.  Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen , 2009, Cancer Immunology, Immunotherapy.

[5]  Fang Wang,et al.  Multiepitope peptide‐loaded virus‐like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma , 2009, Hepatology.

[6]  B. Wang,et al.  Computational Prediction and Identification of Epstein-Barr Virus Latent Membrane Protein 2A Antigen-Specific CD8+ T-Cell Epitopes , 2009, Cellular and Molecular Immunology.

[7]  K. Odunsi,et al.  Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. , 2009, Cancer immunity.

[8]  Shan Wang,et al.  Plac1 is a tumor‐specific antigen capable of eliciting spontaneous antibody responses in human cancer patients , 2008, International journal of cancer.

[9]  B. Ni,et al.  Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy. , 2008, Molecular immunology.

[10]  D. Shen,et al.  The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients. , 2008, Gastroenterology.

[11]  D. Speiser,et al.  Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen , 2008, Proceedings of the National Academy of Sciences.

[12]  U. Şahin,et al.  A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. , 2007, Cancer research.

[13]  B. Ni,et al.  An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180–188) enhanced immunogenicity , 2006, Cancer Immunology, Immunotherapy.

[14]  I. Pollack,et al.  Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. , 2006, Cancer research.

[15]  Z. Ruan,et al.  Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28 , 2006, Cancer Immunology, Immunotherapy.

[16]  V. Apostolopoulos,et al.  Rational Peptide-based vaccine design for cancer immunotherapeutic applications. , 2005, Current medicinal chemistry.

[17]  S. Rosenberg,et al.  Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide , 1994, Cancer Immunology, Immunotherapy.

[18]  S. Holmes,et al.  Diversity and Recognition Efficiency of T Cell Responses to Cancer , 2004, PLoS medicine.

[19]  D. Schlessinger,et al.  PLAC1, a trophoblast‐specific gene, is expressed throughout pregnancy in the human placenta and modulated by keratinocyte growth factor , 2002, Molecular reproduction and development.

[20]  R. Houghten,et al.  Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans , 2002, The Journal of experimental medicine.

[21]  S. Brunak,et al.  Prediction of proteasome cleavage motifs by neural networks. , 2002, Protein engineering.

[22]  F. Tanaka,et al.  Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  F. Lemonnier,et al.  A general strategy to enhance immunogenicity of low‐affinity HLA‐A2.1‐associated peptides: implication in the identification of cryptic tumor epitopes , 2000, European journal of immunology.

[24]  D. Schlessinger,et al.  PLAC1, an Xq26 gene with placenta-specific expression. , 2000, Genomics.

[25]  M. Nakao,et al.  A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. , 1999, Journal of immunology.

[26]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[27]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[28]  Wei Chen,et al.  Immunity to Oncogenic Proteins , 1995, Immunological reviews.

[29]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[30]  C. Rochlitz,et al.  Immune response against tumors. , 1994, Advances in immunology.

[31]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[32]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[33]  V. Engelhard,et al.  Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells , 1988, Journal of Experimental Medicine.